UNSPSC 51372124: Hydrocodone tannate

This classification denotes an opioid receptor agonist and opioid and antitussive agent with the molecular formula C76H52O46.C18H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 68T7388F5H. Most nations, for tariff and trade purposes, schedule hydrocodone tannate under HS 29391100. SMILES:. As of Q4 2014, HYDROCODONE TANNATE remains US FDA's Preferred Term for this commodity.

UNSPSC 51372124 Hydrocodone tannate is a Commodity code that in practice covers pharmaceutical procurement by state and local health and human services agencies, though recent state and local opportunities posted under this code do not consistently align with hydrocodone tannate specifically. Seminole County, Florida and the Texas Health and Human Services Commission have posted solicitations tagged to this code for naloxone systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products—a broader pharmaceutical supply scope than the code name suggests. State health departments, county health agencies, and cooperative purchasing alliances (notably the Minnesota Multistate Cooperative Purchasing Alliance) are the primary issuing bodies, purchasing through a mix of competitive bidding, RFI, and RFP mechanisms to support community health initiatives and state employee health plans.

Recent activity spans Florida, Texas, and Minnesota. The Seminole County IFB (solicitation IFB60459723LAS, response deadline July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building. The Texas HHS Commission issued RFI HHS0017013 (posted April 3, 2026, response deadline April 3, 2026) to explore direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration's MMCAP posted an RFP (solicitation S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across multiple state and local participating jurisdictions, with awarded contracts effective July 1, 2026, requiring compliance with cGMP, DSCSA, and FDA regulations, and vendors must maintain relationships with authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC.